Quick Answer
Protara Therapeutics, Inc. reported Net Income of -$57.44 million for fiscal year 2025.
Protara Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$57.44M | -28.8% |
| 2024 | -$44.60M | -10.3% |
| 2023 | -$40.42M | +38.7% |
| 2022 | -$65.95M | -39.6% |
| 2021 | -$47.25M | -39.1% |
| 2020 | -$33.98M | -333.9% |
| 2019 | -$7.83M | +62.2% |
| 2018 | -$20.73M | +30.8% |
| 2017 | -$29.96M | -5.0% |
| 2016 | -$28.53M | -33.4% |
| 2015 | -$21.38M | -539.6% |
| 2014 | -$3.34M | +57.8% |
| 2013 | -$7.91M | +0.7% |
| 2012 | -$7.97M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$13.26M | -18.2% | +11.4% |
| June 30, 2025 | -$14.96M | -57.3% | -25.6% |
| March 31, 2025 | -$11.91M | -7.4% | -6.2% |
| September 30, 2024 | -$11.22M | -13.8% | -17.9% |
| June 30, 2024 | -$9.51M | +15.8% | +14.3% |
| March 31, 2024 | -$11.10M | -22.7% | -12.5% |
| September 30, 2023 | -$9.86M | -28.2% | +12.7% |
| June 30, 2023 | -$11.29M | -32.3% | -24.9% |
- Protara Therapeutics, Inc. showed a decrease of -28.8% in Net Income compared to the prior fiscal year.
- Over the 2012–2025 period, Protara Therapeutics, Inc.’s net income has declined by 620.7% (from -$7.97 million to -$57.44 million).
- The most recent figure is from Protara Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: